Trending...
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
- LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
- Where Do Missouri Plane Crashes Really Happen? Not Where You'd Think
WEST CHESTER, Pa., Sept. 16, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce the additional close of funds totaling >$5.2M of Series A financing, which includes conversion of all existing convertible notes.
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
Philadelphia area investors BioAdvance (https://www.bioadvance.com/) and Angel Network (https://angelstarventures.com/) Kennett Square, PA lead these additional investments, joined by several other investors.
The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.
VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.
Dr. Rick Jones, BioAdvance Partner said, "BioAdvance is very excited to support the VESTECK "Suture-Tight" technology and team. We appreciate that VESTECK is answering a significant global unmet need for patients and physicians."
More on The PennZone
- ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements
- Prolific Press Publishes 100 Word Fiction Issue #1, the Journal's Debut Anthology
- 100 Word Fiction Releases Issue #2: Forty Stories, One Hundred Words Each
- Kentucky's Plane Crash Data Lands Far from the State's Busiest Airports
- StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.
Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for physicians and patients. Suture-Tight will become the standard of care in EVAR."
Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.
VESTECK CEO Joe Rafferty stated, "We are absolutely honored that our $3.5M Series A round has been over subscribed to this extent, a further recognition of this significant opportunity."
About Vesteck Inc.:
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.
Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.
VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP
MEDIA CONTACTS:
BioAdvance VESTECK, Inc.
Dr. Frederick Jones Joe Rafferty
Partner CEO
(508) 314-5347 610-457-7324
SOURCE VESTECK, Inc.
Related Links
http://VESTECK.com
0 Comments
Latest on The PennZone
- Nearly One-Third of CRE Asset Managers Make Major Capital Decisions on Gut Instinct, New Survey Finds
- RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
- Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
- New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
- Grace Montessori School Earns Prestigious American Montessori Society Accreditation
- Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
- Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
- NaturismRE expands international research programme with Health & Wellbeing Survey
- L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
- LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters
- Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
- Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion
- Obsolete Industrial Expands Its Membership
- FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
- Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
- Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
- Four-Time Olympian Joetta Clark Diggs to Compete at World Masters Athletics Championships in Daegu
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
- The Alistair Apartments Reaches 95% Occupancy in Downtown Lancaster, PA